SG11201707540QA - Method of detecting new immunogenic t cell epitopes and isolating new antigen-specific t cell receptors by means of an mhc cell library - Google Patents

Method of detecting new immunogenic t cell epitopes and isolating new antigen-specific t cell receptors by means of an mhc cell library

Info

Publication number
SG11201707540QA
SG11201707540QA SG11201707540QA SG11201707540QA SG11201707540QA SG 11201707540Q A SG11201707540Q A SG 11201707540QA SG 11201707540Q A SG11201707540Q A SG 11201707540QA SG 11201707540Q A SG11201707540Q A SG 11201707540QA SG 11201707540Q A SG11201707540Q A SG 11201707540QA
Authority
SG
Singapore
Prior art keywords
cell
specific
mhc
immunogenic
library
Prior art date
Application number
SG11201707540QA
Other languages
English (en)
Inventor
Felix Lorenz
Wolfgang Uckert
Christian Ellinger
Dolores Schendel
Original Assignee
Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft
Helmholtz Zentrum München-Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft, Helmholtz Zentrum München-Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) filed Critical Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft
Publication of SG11201707540QA publication Critical patent/SG11201707540QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
SG11201707540QA 2015-03-16 2016-03-15 Method of detecting new immunogenic t cell epitopes and isolating new antigen-specific t cell receptors by means of an mhc cell library SG11201707540QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15159212 2015-03-16
PCT/EP2016/055518 WO2016146618A1 (en) 2015-03-16 2016-03-15 Method of detecting new immunogenic t cell epitopes and isolating new antigen-specific t cell receptors by means of an mhc cell library

Publications (1)

Publication Number Publication Date
SG11201707540QA true SG11201707540QA (en) 2017-10-30

Family

ID=52669552

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201707540QA SG11201707540QA (en) 2015-03-16 2016-03-15 Method of detecting new immunogenic t cell epitopes and isolating new antigen-specific t cell receptors by means of an mhc cell library

Country Status (13)

Country Link
US (2) US11001830B2 (zh)
EP (1) EP3271382B1 (zh)
JP (1) JP6944876B2 (zh)
KR (1) KR102668219B1 (zh)
CN (1) CN107636152B (zh)
AU (1) AU2016232280B2 (zh)
CA (1) CA2979493A1 (zh)
DK (1) DK3271382T3 (zh)
ES (1) ES2790725T3 (zh)
HK (1) HK1248736A1 (zh)
IL (1) IL254511B (zh)
SG (1) SG11201707540QA (zh)
WO (1) WO2016146618A1 (zh)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
JP5971945B2 (ja) 2008-04-17 2016-08-17 ピーディーエス バイオテクノロジー コーポレイションＰｄｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ カチオン性脂質の鏡像異性体による免疫応答の刺激
EP2897639A4 (en) 2012-09-21 2016-05-04 Frank Bedu-Addo IMPROVED VACCINE COMPOSITIONS AND METHODS OF USE
CA3005251A1 (en) 2015-11-13 2017-05-18 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
US11293021B1 (en) 2016-06-23 2022-04-05 Inscripta, Inc. Automated cell processing methods, modules, instruments, and systems
AU2017338827B2 (en) 2016-10-03 2023-08-31 Juno Therapeutics, Inc. HPV-specific binding molecules
KR20240133779A (ko) 2016-10-05 2024-09-04 피디에스 바이오테크놀러지 코퍼레이션 신규한 hpv16 hla-비제한적 t-세포 백신, 조성물 및 이의 사용 방법
WO2018071796A2 (en) * 2016-10-13 2018-04-19 The Johns Hopkins University Compositions and methods for identifying functional anti-tumor t cell responses
EP4039800B1 (en) 2016-11-07 2023-10-25 Genovie AB An engineered multi-component system for identification and characterisation of t-cell receptors and t-cell antigens
ES2900151T3 (es) 2016-11-07 2022-03-16 Genovie Ab Un dispositivo de dos partes para la síntesis del receptor de linfocitos T0 e integración genómica estable en células presentadoras del TCR
EP3354658A1 (en) * 2017-01-25 2018-08-01 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Novel t cell receptors and immune therapy using the same for the treatment of cancer and infectious diseases
US9982279B1 (en) 2017-06-23 2018-05-29 Inscripta, Inc. Nucleic acid-guided nucleases
US10011849B1 (en) 2017-06-23 2018-07-03 Inscripta, Inc. Nucleic acid-guided nucleases
DK3645719T3 (da) 2017-06-30 2022-05-16 Inscripta Inc Automatiserede cellebehandlingsfremgangsmåder, moduler, instrumenter og systemer
JP2020537515A (ja) * 2017-10-03 2020-12-24 ジュノー セラピューティクス インコーポレイテッド Ｈｐｖ特異的結合分子
GB201719169D0 (en) 2017-11-20 2018-01-03 Univ College Cardiff Consultants Ltd Novel T-cell receptor and ligand
WO2019140278A1 (en) * 2018-01-11 2019-07-18 Fred Hutchinson Cancer Research Center Immunotherapy targeting core binding factor antigens
EP3743436A4 (en) * 2018-01-24 2021-10-27 The Council Of The Queensland Institute Of Medical Research HPV IMMUNOTHERAPY
KR20210019993A (ko) 2018-04-05 2021-02-23 주노 쎄러퓨티크스 인코퍼레이티드 Τ 세포 수용체 및 이를 발현하는 조작된 세포
WO2019200004A1 (en) 2018-04-13 2019-10-17 Inscripta, Inc. Automated cell processing instruments comprising reagent cartridges
US10858761B2 (en) 2018-04-24 2020-12-08 Inscripta, Inc. Nucleic acid-guided editing of exogenous polynucleotides in heterologous cells
US10508273B2 (en) 2018-04-24 2019-12-17 Inscripta, Inc. Methods for identifying selective binding pairs
US10557216B2 (en) * 2018-04-24 2020-02-11 Inscripta, Inc. Automated instrumentation for production of T-cell receptor peptide libraries
EP3807642B1 (en) * 2018-05-11 2024-06-12 Memorial Sloan-Kettering Cancer Center Methods for identifying antigen-specific t cell receptors
EP3813974A4 (en) 2018-06-30 2022-08-03 Inscripta, Inc. INSTRUMENTS, MODULES AND METHODS FOR ENHANCED DETECTION OF EDITED SEQUENCES IN LIVING CELLS
US11142740B2 (en) 2018-08-14 2021-10-12 Inscripta, Inc. Detection of nuclease edited sequences in automated modules and instruments
US10532324B1 (en) 2018-08-14 2020-01-14 Inscripta, Inc. Instruments, modules, and methods for improved detection of edited sequences in live cells
US20210301324A1 (en) * 2018-08-24 2021-09-30 Repertoire Genesis Incorporation Method for analyzing functional subunit pair gene of t cell receptor and b cell receptor
CN112955540A (zh) 2018-08-30 2021-06-11 因思科瑞普特公司 在自动化模块和仪器中对经核酸酶经编辑的序列的改进的检测
CN113227368B (zh) 2018-10-22 2023-07-07 因思科瑞普特公司 工程化酶
US11214781B2 (en) 2018-10-22 2022-01-04 Inscripta, Inc. Engineered enzyme
KR102251584B1 (ko) * 2018-11-21 2021-05-14 가톨릭대학교 산학협력단 Ｈｌａ 분자에 제한적인 항원 특이 ｔ 세포 반응 측정 및 예측 방법
CN113631713A (zh) 2019-03-25 2021-11-09 因思科瑞普特公司 酵母中的同时多重基因组编辑
US11001831B2 (en) 2019-03-25 2021-05-11 Inscripta, Inc. Simultaneous multiplex genome editing in yeast
CN110128528B (zh) * 2019-04-28 2020-04-03 天津亨佳生物科技发展有限公司 一种针对egfr l858r基因突变的特异性t细胞受体及其应用
CA3139122C (en) 2019-06-06 2023-04-25 Inscripta, Inc. Curing for recursive nucleic acid-guided cell editing
CA3139124C (en) 2019-06-21 2023-01-31 Inscripta, Inc. Genome-wide rationally-designed mutations leading to enhanced lysine production in e. coli
US10927385B2 (en) 2019-06-25 2021-02-23 Inscripta, Inc. Increased nucleic-acid guided cell editing in yeast
EP3786178A1 (en) 2019-08-30 2021-03-03 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Tcr constructs specific for ebv-derived antigens
WO2021102059A1 (en) 2019-11-19 2021-05-27 Inscripta, Inc. Methods for increasing observed editing in bacteria
WO2021118626A1 (en) 2019-12-10 2021-06-17 Inscripta, Inc. Novel mad nucleases
US10704033B1 (en) 2019-12-13 2020-07-07 Inscripta, Inc. Nucleic acid-guided nucleases
IL292895A (en) 2019-12-18 2022-07-01 Inscripta Inc Cascade/dcas3 complementation assays for in vivo detection of nucleic acid-directed nuclease-edited cells
CN111180071B (zh) * 2019-12-31 2022-02-08 四川大学 高危型hpv型别和宫颈癌前病变阶段关系的计算方法及装置
US10689669B1 (en) 2020-01-11 2020-06-23 Inscripta, Inc. Automated multi-module cell processing methods, instruments, and systems
EP4096770A1 (en) 2020-01-27 2022-12-07 Inscripta, Inc. Electroporation modules and instrumentation
CN111429965B (zh) * 2020-03-19 2023-04-07 西安交通大学 一种基于多连体特征的t细胞受体对应表位预测方法
US20230348558A1 (en) * 2020-03-23 2023-11-02 The Council Of The Queensland Institute Of Medical Research Compositions and methods for targeting hpv-infected cells
US20210332388A1 (en) 2020-04-24 2021-10-28 Inscripta, Inc. Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells
US11787841B2 (en) 2020-05-19 2023-10-17 Inscripta, Inc. Rationally-designed mutations to the thrA gene for enhanced lysine production in E. coli
CN111574615A (zh) * 2020-05-23 2020-08-25 湖南源品细胞生物科技有限公司 一种tcr富集克隆型及其获取方法与应用
WO2021237932A1 (zh) * 2020-05-23 2021-12-02 湖南源品细胞生物科技有限公司 Tcr富集克隆型及其获取方法与应用
WO2021243695A1 (en) * 2020-06-05 2021-12-09 Guangdong Tcrcure Biopharma Technology Co., Ltd. Tcr-t cell therapy targeting epstein-barr virus
CN111647070B (zh) * 2020-06-17 2022-06-03 深圳豪石生物科技有限公司 T细胞受体或其抗原结合片段及应用
WO2022060749A1 (en) 2020-09-15 2022-03-24 Inscripta, Inc. Crispr editing to embed nucleic acid landing pads into genomes of live cells
WO2022086185A1 (ko) * 2020-10-20 2022-04-28 연세대학교 산학협력단 단일 세포 분석법을 이용한 tcr-항원의 특이성을 확인하는 방법
US11512297B2 (en) 2020-11-09 2022-11-29 Inscripta, Inc. Affinity tag for recombination protein recruitment
CN113999815A (zh) * 2020-12-08 2022-02-01 深圳市人民医院 靶向hpv16相关宫颈癌的tcr-t细胞建立方法
CN112501269B (zh) * 2020-12-15 2022-02-18 清华大学 一种快速鉴定高亲和力tcr抗原交叉反应活性的方法
EP4267725A1 (en) * 2020-12-22 2023-11-01 National University of Singapore Artificial antigen-presenting cell
WO2022146497A1 (en) 2021-01-04 2022-07-07 Inscripta, Inc. Mad nucleases
WO2022150269A1 (en) 2021-01-07 2022-07-14 Inscripta, Inc. Mad nucleases
US11884924B2 (en) 2021-02-16 2024-01-30 Inscripta, Inc. Dual strand nucleic acid-guided nickase editing
EP4091627A1 (en) 2021-05-21 2022-11-23 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Tcr constructs specific for magea4-derived epitopes
WO2023142683A1 (zh) * 2022-01-27 2023-08-03 上海市第一人民医院 靶向巨细胞病毒抗原的tcr和表达其的t细胞及应用
CN116199766B (zh) * 2022-06-22 2024-03-12 清华大学 筛选tcr的方法及其分离的tcr
EP4299734A1 (en) * 2022-07-01 2024-01-03 ETH Zurich Cell line for discovering tcr antigens and uses thereof
EP4328239A1 (en) 2022-08-26 2024-02-28 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Immunotherapeutics based on magea1-derived epitopes
WO2024131372A1 (zh) * 2022-12-23 2024-06-27 上海市第一人民医院 靶向巨细胞病毒pp65的TCR和表达其的T细胞及应用
WO2024139780A1 (zh) * 2022-12-26 2024-07-04 上海市第一人民医院 靶向巨细胞病毒pp65的T细胞受体和表达其的T细胞及应用
EP4393942A1 (en) * 2022-12-29 2024-07-03 Keshihua (Nanjing) Biotechnology Co., Ltd Tcr, polypeptide, expression vector, host cell, pharmaceutical composition and method for obtaining tcr

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU723355B2 (en) * 1996-05-23 2000-08-24 Scripps Research Institute, The MHC class II antigen presenting systems and methods for activating CD4+ T cells
KR100922809B1 (ko) * 1999-05-06 2009-10-21 웨이크 포리스트 유니버시티 면역 반응을 유발하는 항원을 동정하기 위한 조성물과 방법
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
JP2005533855A (ja) 2002-07-24 2005-11-10 インターツェル・アクチェンゲゼルシャフト 病原性ウイルスからの別のリーディングフレームによりコードされる抗原
CA2484339A1 (en) * 2002-09-13 2004-03-25 Intercell Ag Method for isolating hepatitis c virus peptides
DK1576967T3 (da) 2004-03-18 2008-01-21 Pasteur Institut Rekombinant protein, der bærer epitoper fra det humane papillomvirus indsat i et adenylatcyclaseprotein eller et fragment deraf samt dets terapeutiske anvendelse
HUE038833T2 (hu) 2005-08-05 2018-11-28 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh Antigénspecifikus T-sejtek létrehozása
SI1760089T1 (sl) * 2005-09-05 2009-12-31 Immatics Biotechnologies Gmbh S tumorjem povezani peptidi, ki se veĹľejo na molekule humanega levkocitnega antigena (HLA) razreda I ali II in ustrezno cepivo proti raku
EP1762575A1 (en) * 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
WO2011024482A1 (ja) 2009-08-29 2011-03-03 株式会社バイオメッドコア 抗原特異的ｔ細胞誘導能測定法
DK2618835T3 (en) * 2010-09-20 2017-08-28 Biontech Cell & Gene Therapies Gmbh ANTIGEN-SPECIFIC T-CELL RECEPTORS AND T-CELL EPITOPES
US10023657B2 (en) * 2010-10-01 2018-07-17 Ludwig Institute For Cancer Research Ltd. Reversible protein multimers, methods for their production and use
AU2016222788B2 (en) * 2015-02-24 2022-03-31 Adaptive Biotechnologies Corp. Methods for diagnosing infectious disease and determining HLA status using immune repertoire sequencing

Also Published As

Publication number Publication date
CN107636152A (zh) 2018-01-26
DK3271382T3 (da) 2020-05-04
US20180073013A1 (en) 2018-03-15
KR102668219B1 (ko) 2024-05-28
JP2018509911A (ja) 2018-04-12
EP3271382A1 (en) 2018-01-24
AU2016232280A1 (en) 2017-10-12
CN107636152B (zh) 2021-09-21
CA2979493A1 (en) 2016-09-22
EP3271382B1 (en) 2020-02-12
IL254511B (en) 2021-12-01
ES2790725T3 (es) 2020-10-29
AU2016232280B2 (en) 2018-05-31
WO2016146618A1 (en) 2016-09-22
KR20170126500A (ko) 2017-11-17
US11001830B2 (en) 2021-05-11
IL254511A0 (en) 2017-11-30
US20210261947A1 (en) 2021-08-26
JP6944876B2 (ja) 2021-10-06
HK1248736A1 (zh) 2018-10-19

Similar Documents

Publication Publication Date Title
HK1248736A1 (zh) 通過mhc細胞文庫檢測新免疫原性t細胞表位和分離新抗原-特異性t細胞受體的方法
HUE056387T2 (hu) Eljárás antigénspecifikus CD8-pozitív T-sejtek indukálására
HK1224340A1 (zh) 自身癌抗原特異性 細胞的分離及增殖方法
IL253627B (en) Prediction of t-cell epitopes used for vaccination
IL256511B (en) An immunoreactive cell expressing a chimeric antigen receptor and a chimeric co-stimulatory receptor
EP3277294C0 (en) METHOD FOR IDENTIFYING HUMAN COMPATIBILITY-SPECIFIC T CELL RECEPTORS FOR AN ANTIGEN TARGET
HK1256130A1 (zh) 用於嵌合抗原受體和其他受體的表達的t細胞
EP3236409A4 (en) System for predicting residual lifespan of fire-damaged concrete structure and method therefor
EP3010157A4 (en) METHOD FOR DETECTING ELECTRICAL QUANTITY OF DEVICE, AND DEVICE AND SYSTEM THEREOF
HK1243206A1 (zh) 用於資源的地理位置驗證的方法和系統
EP3161989A4 (en) Method and apparatus of ue and enb for mtc with narrowband deployment
NO346582B1 (en) Method and system for seismic analysis
EP3134735A4 (en) Methods of measuring antigen-specific t cells
AP2016009458A0 (en) Grouted rock support testing apparatus and method
HK1253693A1 (zh) 產生抗t細胞受體的抗體的方法
ZA201703845B (en) Method for detecting earthquakes and locating epicentres by means of a network of lights
HK1232288A1 (zh) 用於測量 的反應性的方法
SG11201706418QA (en) Method for antigen loading of dendritic cells and vaccine
GB201807846D0 (en) System and method for foundation of wellheads
EP3025404A4 (en) Method and apparatus of secure charging for device-to-device service
DK3224894T3 (da) Fremgangsmåde til symmetrering af et energilagersystem
GB201401892D0 (en) System and method for measuring properties of a charges particle beam
HK1257599A1 (zh) 一種促進胰島素受體底物-2表達的方法
EP3211583A4 (en) Method for estimating earthquake resistance magnitude of existing structure and system therefor
IL234216A0 (en) Method and system for causing an explosion inside tunnels